The company’s Phase III trial of nemvaleukin alfa alongside Keytruda saw just a 0.3 month gain in overall survival over other chemotherapy options.

Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa. Click here to read an ...